Animal and cellular models for hypolipidemic drugs

Area of Science:

• Pharmacology
• Cardiovascular Research
• Preclinical Drug Development

Background:

• Robust preclinical investigation is essential for developing safe and effective lipid-lowering agents.
• The choice of cellular and animal models significantly impacts the success of drug development.

Purpose of the Study:

• To highlight the critical role of preclinical models in evaluating lipid-lowering drugs.
• To discuss various models used for assessing drug effects on lipid metabolism and atherosclerosis.

Main Methods:

• Utilizing established animal models like apolipoprotein E- and LDL-receptor knockout mice.
• Employing in vitro and in vivo models to assess reverse cholesterol transport.
• Testing drug efficacy in preventing triglyceride-rich lipoprotein assembly and enhancing LDL clearance.

Main Results:

• Animal models effectively evaluate drug actions on lipoprotein metabolism and atherosclerotic pathways.
• Models now exist to test drugs that enhance high-density lipoprotein (HDL) function and reverse cholesterol transport.
• Preclinical studies provide necessary, though not sufficient, data for drug approval.

Conclusions:

• The selection of appropriate preclinical models is crucial for the development of lipid-lowering therapies.
• Advanced models for assessing HDL function and reverse cholesterol transport are now available.
• Positive preclinical results are a prerequisite but not a guarantee for clinical approval.